Zipeprol: Preclinical assessment of abuse potential

M. D. Acteo, E. Bowman, E. Butelman, J. A. English, L. Harris, A. E. Jacobson, M. V. Mattson, F. Medzihradsky, G. Patrick, J. K. Rowlett, C. B. Smith, G. Winger, J. H. Woods, W. L. Woolverton

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Zipeprol was evaluated in a number of in vitro and in vivo assays predictive of stimulant, depressant, or opioid abuse potential. Zipeprol had affinity for μ and κ opioid binding sites as well as a binding sites. However, it failed to exert opioid-like agonist actions in rodents, and did not attenuate withdrawal signs in morphine- or pentobarbital-dependent rats. Zipeprol did not substitute for either amphetamine or pentobarbital in drug discrimination assays in rhesus monkeys. On the other hand, it suppressed morphine withdrawal signs in rhesus monkeys in two assays, and it acted as a quadazocine-sensitive reinforcer in monkeys trained to self-inject alfentanil. Zipeprol also acted as a reinforcer in monkeys trained to self-inject methohexital. In a dose range of 10-18 mg/kg, zipeprol induced convulsions in monkeys. Zipeprol appears to have abuse potential and a novel spectrum of action involving both opioid and non-opioid effects.

Original languageEnglish (US)
Pages (from-to)93-104
Number of pages12
JournalDrug and Alcohol Dependence
Issue number2
StatePublished - Oct 1996
Externally publishedYes


  • Abuse potential
  • Opioid abuse
  • Piperazine
  • Zipeprol

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Zipeprol: Preclinical assessment of abuse potential'. Together they form a unique fingerprint.

Cite this